Citations 1
P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)
Hoering, Antje , Sexton, Rachel , Valent, Jason , Rosenzweig, M., Zonder, Jeff, Dhodapkar, M., Zimmerman, T., Voorhees, Peter M. , Durie, Brian, Richardson, PG, Usmani, Saad Z. , Ailawadhi, Sikander , Sexton, R., Lipe, Brea , Valent, Jason Neil , Rosenzweig, Michael , Callander, Natalie S. , Rajkumar, S. Vincent , Orlowski, Robert Z.
HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 855-856
